Search Results

yner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients

Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients

Intensity Therapeutics, Inc. announces that the Company executed a collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK to conduct a Phase 2 randomized, controlled trial evaluating clinical and biological effects of intratumoral INT230-6 followed by the standard of care immuno/chemotherapy vs. SOC immune/chemotherapy alone in early-stage triple-negative breast cancer in 54 patients in Switzerland and selected countries in Europe.

NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, welcomes Dr. Yona Geffen, as a consultant, to support the Company’s preclinical and clinical activities.

Strategic Advisory for Leading Therapeutics Innovation Inc. (SALTI) is proud to announce its official launch, poised to set a new standard in life sciences consulting.

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

AmerisourceBergen Specialty Group, LLC is issuing notice to individuals who may have been impacted by a data security incident.